March 10, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational ...

A newly published pooled analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial and the CAO/ARO/AIO-12 trial by the German Rectal Cancer Study Group has confirmed the ...

That was a huge upgrade over the .216/.304/.364 they hit from March to August. We’re talking about just one month, and some of Seattle’s opponents were out of contention and playing out the ...

Patients with IgA nephropathy (IgAN) (n=14) received subcutaneous doses of ARO-C3 (400 mg) on Days 1, 29, and 113 and were followed through Day 169 Pharmacodynamic effects Maximum mean reduction in C3 ...

- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to ...

Divyashakti Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 69.17 Crore) operating in Mining sector. Divyashakti Ltd. key Products/Revenue Segments include ...

1 The 3rd Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China 2 Department of Acupuncture & Tuina, Hunan University of Traditional Chinese Medicine, Changsha ...